Maxima40 mg

Maxima is a proton pump inhibitor used to reduce gastric acid secretion. Its indications are classified below by strength of evidence.

Established / Approved Uses

• Gastroesophageal Reflux Disease (GERD): Treatment of heartburn and other symptoms of GERD, healing of erosive esophagitis, and maintenance of healing to prevent relapse.
• Duodenal and Gastric Ulcer: Treatment, and risk reduction of NSAID-associated gastric ulcer in patients who require continued NSAID use.
• Zollinger-Ellison Syndrome: Long-term management of pathological hypersecretory conditions.

Uses Requiring Combination Therapy

• Helicobacter pylori Eradication: Maxima is used together with amoxicillin and clarithromycin (triple therapy) to eradicate H. pylori and reduce the risk of duodenal ulcer recurrence. It is not effective as monotherapy for this indication.

Guideline-Supported / Adjunct Uses

• Prevention of NSAID-associated gastric ulcer in patients with a history of ulcer who require ongoing NSAID therapy.
• Adjunct use in stress ulcer prophylaxis in critically ill patients per institutional protocols (not a primary FDA-labeled indication for all formulations).

Each unit of Esomeprazole Magnesium Trihydrate contains esomeprazole (as the magnesium trihydrate salt) as the active pharmaceutical ingredient, equivalent to 20 mg or 40 mg of esomeprazole base, depending on strength and formulation.

It is formulated as enteric-coated delayed-release tablets or capsules (to protect the acid-labile active ingredient from gastric acid) and, in some markets, as a lyophilized powder for injection (esomeprazole 40 mg/vial) for intravenous use when oral therapy is not feasible.

Maxima is the S-isomer of omeprazole and belongs to the proton pump inhibitor (PPI) class of antisecretory drugs. It works by irreversibly blocking the final step of gastric acid production, providing sustained suppression of acid secretion for the treatment of acid-related disorders of the upper gastrointestinal tract.

It is available as enteric-coated oral tablets/capsules and as an intravenous injection for short-term use in patients unable to take oral medication.

Proton Pump Inhibitor (PPI) / Gastric Acid Suppressant

Esomeprazole Magnesium Trihydrate is a substituted benzimidazole that is converted to its active sulfenamide form within the acidic environment of gastric parietal cell canaliculi. This active form binds covalently to cysteine residues on the H+/K+-ATPase (proton pump) enzyme, irreversibly inhibiting the final common pathway of gastric acid secretion regardless of the stimulus (histamine, acetylcholine, or gastrin).

Because inhibition is irreversible, acid suppression persists until new proton pump molecules are synthesized, allowing once-daily dosing despite a short plasma half-life (approximately 1-1.5 hours). Maximal acid-suppressive effect is typically reached after 3-5 days of continuous once-daily dosing. Esomeprazole Magnesium Trihydrate is metabolized primarily by the hepatic CYP2C19 enzyme and, to a lesser extent, CYP3A4.

Maxima delayed-release tablets/capsules should be swallowed whole, at least one hour before a meal, and should not be crushed or chewed, as this would destroy the enteric coating that protects the drug from gastric acid degradation.

• For patients unable to swallow capsules, the capsule may be opened and its pellets mixed with a small amount of applesauce or non-carbonated water and swallowed immediately without chewing (check the specific product's labeling).
• For nasogastric/orogastric tube administration, follow the specific product insert for suspension preparation.
• The intravenous formulation should be administered by a healthcare professional as an injection over at least 3 minutes or as an infusion over 10-30 minutes, and should be switched to oral therapy as soon as feasible.

Maxima significantly reduces gastric acidity, which can alter absorption of pH-dependent drugs, and it is metabolized via CYP2C19, creating potential for clinically significant interactions.

• Clopidogrel: Concomitant use reduces formation of clopidogrel's active metabolite via CYP2C19 inhibition, potentially reducing its antiplatelet effect and increasing cardiovascular risk. Concomitant use should be avoided when possible.
• Rilpivirine-containing products: Co-administration significantly decreases rilpivirine plasma concentrations, risking loss of virologic response and resistance; concomitant use is contraindicated (see Contraindications).
• Methotrexate (high-dose): PPIs may elevate and prolong methotrexate and its metabolite levels, increasing toxicity risk; temporary interruption of Maxima may be considered.
• Warfarin: May increase INR and prothrombin time; monitor coagulation parameters.
• Drugs dependent on gastric pH for absorption (e.g., ketoconazole, itraconazole, atazanavir, iron salts, mycophenolate mofetil): Absorption may be significantly reduced due to elevated gastric pH.
• CYP2C19 substrates (e.g., diazepam, citalopram, cilostazol): Plasma concentrations of these drugs may increase; dose adjustment may be needed.
• Strong CYP3A4/2C19 inducers (e.g., rifampin, St. John's Wort): May substantially decrease esomeprazole plasma levels, reducing efficacy.
• Tacrolimus: May increase serum tacrolimus concentrations; monitoring is recommended.

Most adverse effects associated with Maxima are mild and transient.

Common (≥1%)

• Headache
• Diarrhea
• Nausea
• Flatulence
• Abdominal pain
• Constipation
• Dry mouth

Less Common / Serious

• Hypomagnesemia, vitamin B12 deficiency, and increased fracture risk with prolonged use (see Precautions and Warnings)
• Clostridioides difficile-associated diarrhea
• Hypersensitivity reactions including rash, urticaria, angioedema, and rarely anaphylaxis or severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis)
• Acute interstitial nephritis
• Cutaneous and systemic lupus erythematosus (rare)

Pregnancy: Data on the use of Maxima in pregnant women are limited. Animal reproduction studies have not shown clear evidence of harm, but adequate and well-controlled human studies are lacking. Maxima should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use.

Lactation: Esomeprazole is excreted in human breast milk. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue breastfeeding or discontinue Maxima, taking into account the importance of treatment to the mother. Consult a physician before use while breastfeeding.

The following precautions apply to the use of Maxima, particularly with long-term (generally more than 1 year) or high-dose use:

• Bone fracture risk: Long-term, multiple-daily-dose PPI therapy is associated with an increased risk of osteoporosis-related fractures of the hip, wrist, and spine.
• Hypomagnesemia: Prolonged use (generally ≥3 months) may cause low serum magnesium, which can present as tetany, arrhythmia, or seizure; consider periodic magnesium monitoring for long-term therapy or concomitant use with digoxin or diuretics.
• Vitamin B12 deficiency: Reduced gastric acid may impair vitamin B12 absorption with prolonged (>3 years) therapy.
• Clostridioides difficile-associated diarrhea: Acid suppression increases the risk of gastrointestinal infection; consider this diagnosis for persistent diarrhea that does not improve.
• Masking of gastric malignancy: Symptomatic response does not exclude gastric malignancy; consider further evaluation in patients with alarm symptoms or those not responding adequately.
• Rebound acid hypersecretion: May occur after stopping therapy, particularly after long-term use; consider tapering rather than abrupt discontinuation.
• Fundic gland polyps: Risk increases with long-term use, especially beyond one year; use the lowest effective dose for the shortest duration appropriate to the condition.
• Clopidogrel co-administration: Use with caution due to reduced antiplatelet effect (see Interaction).
• Not a substitute for endoscopic evaluation where indicated.

Reported experience with overdose of Maxima is limited. Doses well above the recommended range have generally been tolerated without severe symptoms, though confusion, blurred vision, tachycardia, nausea, sweating, flushing, headache, dry mouth, and other symptoms have been reported. There is no specific antidote.

In case of suspected overdose, seek immediate medical attention or contact a poison control center. Treatment is supportive and symptomatic; Maxima is highly protein-bound and is not expected to be efficiently removed by dialysis.

Store at room temperature (below 30°C), protected from light and moisture. Keep the container tightly closed and out of the reach and sight of children. The reconstituted intravenous solution should be used within the time specified on the product label (see Reconstitution).

Renal impairment: No dosage adjustment of Maxima is required in patients with renal impairment; data in severe renal impairment are limited.

Hepatic impairment: No adjustment is needed for mild-to-moderate impairment. In severe hepatic impairment, the maximum dose should not exceed 20 mg once daily.

Elderly: No dosage adjustment is generally necessary based on age alone; consider overall fracture and nutritional risk with long-term use (see Precautions and Warnings).

Pediatric use: See Pediatric Uses.

Pregnancy and lactation: See Pregnancy and Lactation.

Duration of Maxima therapy depends on indication: symptomatic GERD typically 4 weeks; erosive esophagitis healing 4-8 weeks with maintenance therapy continued as needed and reassessed periodically; H. pylori eradication regimens last 10 days; NSAID-ulcer risk reduction may extend up to 6 months; and Zollinger-Ellison syndrome may require long-term, individualized treatment for as long as clinically indicated. Use the lowest effective dose for the shortest duration appropriate to the clinical situation, particularly for long-term maintenance therapy.

For the intravenous injection formulation of Maxima (40 mg/vial powder for solution): reconstitute with 5 mL of 0.9% Sodium Chloride Injection for direct intravenous injection over at least 3 minutes, or further dilute in 50 mL of 0.9% Sodium Chloride Injection (or other compatible diluent per product labeling) for intravenous infusion over 10-30 minutes. Use the reconstituted/diluted solution within the time window specified in the product's package insert and discard any unused portion. Do not administer with other medications through the same line.

Proton Pump Inhibitors (PPIs); Antisecretory / Gastric Acid Suppressants; Substituted Benzimidazoles

Esomeprazole Magnesium Trihydrate is a proton pump inhibitor that irreversibly binds to and inhibits the H+/K+-ATPase enzyme system at the secretory surface of the gastric parietal cell. This blocks the final step of acid production, suppressing both basal and stimulated gastric acid secretion irrespective of the stimulating agent.

The safety and effectiveness of Maxima for short-term treatment of GERD have been established in pediatric patients 1 year to 17 years of age; dosing in this age group is weight-based and lower than typical adult doses.

Safety and efficacy in children younger than 1 year of age, and for indications other than GERD, have not been established; use in these populations is not recommended outside specialist guidance.